Skip to main content
Figure 5 | BMC Pulmonary Medicine

Figure 5

From: Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial

Figure 5

EELV during exercise at baseline and at Week 3. EELV during constant work rate cycle ergometry in patients receiving a) placebo, or b) aclidinium 400 μg BID. EELV was assessed at rest, at isotime, and at end of exercise at baseline and at Week 3 (ITT population). Data are descriptive and reported as mean ± standard deviation. EELV was assessed as IC subtracted from mean TLC 2 h post-dose. Mean isotime was calculated as 386 seconds. BID, twice daily; EELV, end-expiratory lung volumes; IC, inspiratory capacity; ITT, intent-to-treat; TLC, total lung capacity.

Back to article page